Supplementary Figure 1 (A-G):
Levels of several biomarkers measured in serum from UC patients treated with 25, 50 or 100 mg ABX464 daily or placebo for 8 weeks.

Supplementary Figure 2: Effects of ABX464 on CD4+ subsets in the MLNs of healthy mice. Cells in the MLNs of untreated (H$_2$O group) and treated (H2O+ABX464) healthy mice were collected and stained to determine proportions of IL17 secretors, IFNg secretors, Treg cells and IL-22 secretors. In these non-inflammatory mice, there was no significant effects of ABX464 treatment on IL17 secretors, IL22, and IFNg secretors cell population, while a slight but significant effect was observed on Treg cells. Dots represent samples from individual mice (N= 9 mice *per* group) and mean +/- standard error of the mean (SEM) are reported. Ordinary one-way ANOVA or Kruskal-Wallis tests with Dunn's multiple comparison test (*=p<0.05).

Supplementary Figure 3: Kinetic analysis of the effects of ABX464 on cytokine secretion by colons of DSS-induced mice. The colons of untreated healthy mice (H2O group, blue curves) or DSS-induced colitis mice treated by ABX464 (DSS+ABX464, green curves), or untreated (DSS, orange curve) were cultured *ex vivo* at days 3, 6, 7, 8, 9 and 10 of an acute DSS experiment and assessed for cytokines secretions. For several cytokines for which there was no difference at Day 10, significant differences were observed at the preceding days. Dots represent mean +/- standard error of the mean (SEM) for each time-point. The statistics are based on the fold change compared to DSS. Kruskal-Wallis with Dunn's multiple comparison test (*=$p<0.05$, **=$p<0.01$***=$p<0.001$). N=10 mice/time-point *per* group.